Saturday 17 October 2026
Export WVE’s income statement to Excel — free account
WAVE Life Sciences Ltd.
In the quarter to June 2026, revenue fell 73.9%, EPS fell 9.68% and free cash flow fell 17.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.12
0.07
−2.19%
Follow WVE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (68.31%) | (53.72%) | (56.16%) | (91.62%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
4 | 3 | 3 | 4 | |
| (49.95%) | (42.11%) | (41.26%) | (40.66%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(43.68%) | (35.41%) | (38.77%) | (88.50%) | |
Average Days of Receivables |
4.96 | 0.00 | 10.90 | 33.42 | |
Free Cash Flow per Share |
(0.95) | (0.92) | (1.12) | (1.18) | |
Free Cash Flow |
(193.15) | (185.00) | (188.21) | (198.17) | |
Capital Expenditures |
(1.57) | (0.99) | (0.72) | (0.80) | |
| Other line items | |||||
Cash ROIC |
(20.46%) | (17.51%) | (16.80%) | (61.78%) | |
Accounts Receivable Turnover |
56.60 | 0.00 | 33.30 | 7.03 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
302.00% | 264.07% | 427.78% | 159.86% | |
Selling, General and Administrative Expense of Revenue |
131.36% | 110.14% | 176.31% | 64.61% | |
Share Based Compensation of Revenue |
51.43% | 40.51% | 58.45% | 19.10% | |
Operating CF/Net income |
0.95 | 1.00 | 0.92 | 1.62 | |
Depreciation/Fixed assets |
1.34 | 1.27 | 1.20 | 1.07 | |
Capex/Depreciation |
(0.17) | (0.11) | (0.08) | (0.09) | |
Revenue per Share |
0.32 | 0.36 | 0.25 | 0.65 | |
Operating CF per Share |
(0.94) | (0.92) | (1.11) | (1.18) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.02 | 0.01 |
Columns are period end dates